Do Histologically Aggressive Subtypes of Papillary Thyroid Microcarcinoma have Worse Clinical Outcome than Non-Aggressive Papillary Thyroid Microcarcinoma Subtypes? A Multicenter Cohort Study

Abstract

Histologically aggressive micropapillary thyroid carcinomas (PTMC) subtypes are thought to be associated with an aggressive clinical course. However, evidence for unfavorable clinical outcomes in patients with aggressive PTMC subtypes is not clear. In this study, we intended to determine the difference in clinical outcomes between patients with aggressive and non-aggressive PTMC subtypes. In this multicenter cohort study, the computer-recorded clinical and histopathological data of patients who underwent thyroid surgery between January 2000 - January 2021 in 9 referral centers and were diagnosed as PTMC were analyzed. A total of 1585 patients [female 1340 (84.5%), male 245 (15.5%), mean age 47.9±11.63 years), with a mean follow-up time of 66.55±37.16 months], were included in the study. Ninety-eight cases were diagnosed as aggressive and 1487 as non-aggressive subtypes. Persistent/recurrent disease was observed in 33 (33.7% )and 41 (2.8%) patients with aggressive and non-aggressive subtypes (p<0.001). Diseases-free survival rates were markedly lower in patients with aggressive than in those with non-aggressive PTMC subtypes (66.3 vs. 94.8%, log-rank p<0.001). Moreover, in multivariate analysis, aggressive histology was an independent predictor of persistent/recurrent disease, after controlling for other contributing factors (HR 5.78, 95% CI 3.32–10, p<0.001). Patients with aggressive PTMC subtypes had higher rates of incomplete biochemical and structural response than patients with non-aggressive subtypes as well (p<0.001). Aggressive PTMC subtypes share many characteristics with histologically identical tumors>1 cm in size. Therefore, the histopathological subtype of PTMC should be taken into consideration to tailor a personalized management plan.

Key words

papillary microcarcinoma - aggressive subtype - clinical outcome

Publication History

Received: 01 December 2022

Accepted after revision: 10 February 2023

Accepted Manuscript online:
10 February 2023

Article published online:
06 April 2023

• References

• 1 Hughes DT, Haymart MR, Miller BS. et al. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid 2011; 21: 231-236
• 2 Wartofsky L. Management of papillary microcarcinoma: primum non nocere?. J Clin Endocrinol Metab 2012; 97: 1169-1172
• 3 Coca-Pelaz A, Shah JP, Hernandez-Prera JC. et al. Papillary thyroid cancer – aggressive variants and impact on management: a narrative review. Adv Ther 2020; 37: 3112-3128
• 4 Lloyd R, Osamura R, Klöppel G. et al. WHO classification of tumours of endocrine organs. 4. Lyon: International Agency for Research on Cancer; 2017
• 5 Haugen BR, Alexander EK, Bible KC. et al. 2015; American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016: 1-133
• 6 Kuo EJ, Goffredo P, Sosa JA. et al. Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis. Thyroid 2013; 23: 1305-1311
• 7 Carcangiu ML, Bianchi S. Diffuse sclerosing variant of papillary thyroid carcinoma. Clinicopathologic study of 15 cases. Am J Surg Pathol 1989; 13: 1041-1049
• 8 Carling T, Ocal IT, Udelsman R. Special variants of differentiated thyroid cancer: does it alter the extent of surgery versus well-differentiated thyroid cancer?. World J Surg 2007; 31: 916-923
• 9 Albareda M, Puig-Domingo M, Wengrowicz S. et al. Clinical forms of presentation and evolution of diffuse sclerosing variant of papillary carcinoma and insular variant of follicular carcinoma of the thyroid. Thyroid 1998; 8: 385-391
• 10 Fukushima M, Ito Y, Hirokawa M, Akasu H. et al. Clinicopathologic characteristics and prognosis of diffuse sclerosing variant of papillary thyroid carcinoma in Japan: an 18-year experience at a single institution. World J Surg 2009; 33: 958-962
• 11 Kazaure HS, Roman SA, Sosa JA. Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients. Annals Surg Oncol 2012; 19: 1874-1880
• 12 Canberk S, Montezuma D, Ince U. et al. Variants of papillary thyroid carcinoma: an algorithmic cytomorphology-based approach to cytology specimens. Acta Cytol 2020; 64: 288-298
• 13 Van Dijk SPJ, Coerts HI, Gunput STG. et al. Assessment of radiofrequency ablation for papillary microcarcinoma of the thyroid: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg 2022; 148: 317-325
• 14 Miyauchi A. Clinical trials of active surveillance of papillary microcarcinoma of the thyroid. World J Surg 2016; 40: 516-522
• 15 Song E, Jeon MJ, Oh HS. et al. Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classic papillary thyroid carcinoma?. Eur J Endocrinol 2018; 179: 135-142
• 16 Kim M, Cho SW, Park YJ. et al. Clinicopathological characteristics and recurrence-free survival of rare variants of papillary thyroid carcinomas in Korea: a retrospective study. Endocrinol Metab (Seoul) 2021; 36: 619-627
• 17 Baloch ZW, Asa SL, Barletta JA. et al. Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr Pathol 2022; 33: 27-63
• 18 Amin MB, Edge S, Greene F. et al. AJCC Cancer Staging Manual. 8th ed.. Berlin: Springer Verlag; 2017
• 19 Cooper DS, Doherty GM. et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167e1214
• 20 Zuhur SS, Aggul H, Çelik M. et al. Can age at diagnosis and sex improve the performance of the American thyroid association risk stratification system for prediction of structural persistent and recurrent disease in patients with differentiated thyroid carcinoma? A multicenter study. Endocr Pract 2022; 28: 30-35
• 21 Haymart MR. Progress and challenges in thyroid cancer management. Endocr Pract 2021; 27: 1260-1263
• 22 Van Gerwen M, Alsen M, Lee E. et al. Recurrence-free survival after total thyroidectomy and lobectomy in patients with papillary thyroid microcarcinoma. J Endocrinol Invest 2021; 44: 725-736
• 23 Ardito G, Revelli L, Giustozzi E. et al. Aggressive papillary thyroid microcarcinoma: prognostic factors and therapeutic strategy. Clin Nucl Med 2013; 38: 25-28
• 24 Mehanna H, Al-Maqbili T, Carter B. et al. Differences in the recurrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma: a systematic review and meta-analysis of 21329 person-years of follow-up. J Clin Endocrinol Metab 2014; 99: 2834-2843
• 25 Chou R, Dana T, Haymart M. et al. Active surveillance versus thyroid surgery for differentiated thyroid cancer: a systematic review. Thyroid 2022; 4: 351-367
• 26 Longheu A, Canu GL, Cappellacci F. et al. Tall cell variant versus conventional papillary thyroid carcinoma: a retrospective analysis in 351 consecutive patients. J Clin Med 2020; 10: 70
• 27 Medas F, Canu GL, Cappellacci F. et al. Predictive factors of lymph node metastasis in patients with papillary microcarcinoma of the thyroid: retrospective analysis on 293 cases. Front Endocrinol (Lausanne) 2020; 11: 551
• 28 Vuong HG, Long NP, Anh NH. et al. Papillary thyroid carcinoma with tall cell features is as aggressive as tall cell variant: a meta-analysis. Endocr Connect 2018; 7: R286-R293
• 29 Vuong HG, Kondo T, Pham TQ. et al. Prognostic significance of diffuse sclerosing variant papillary thyroid carcinoma: a systematic review and meta-analysis. Eur J Endocrinol 2017; 176: 433-441
• 30 Vuong HG, Odate T, Duong UNP. et al. Prognostic importance of solid variant papillary thyroid carcinoma: A systematic review and meta-analysis. Head Neck 7 2018; 40: 1588-1597
• 31 Chen JH, Faquin WC, Lloyd RV, Nosé V. Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma. Mod Pathol 2011; 24: 739-749
• 32 Usluogullari CA, Onal ED, Ozdemir E. et al. A retrospective analysis of prognostic factors predictive of lymph-node metastasis and recurrence in thyroid papillary microcarcinoma. Minerva Endocrinol 2015; 40: 15-22
• 33 Papachristos A, Do K, Tsang VH. et al. Outcomes of papillary thyroid microcarcinoma presenting with palpable lateral lymphadenopathy. Thyroid 2022; 32: 1086-1093
• 34 Carvalho AY, Kohler HF, Gomes CC. et al. Predictive factors of recurrence of papillary thyroid microcarcinomas: analysis of 2,538 patients. Int Arch Otorhinolaryngol 2021; 25: e585-e593
• 35 Wen X, Jin Q, Cen X. et al. Clinicopathologic predictors of central lymph node metastases in clinically node-negative papillary thyroid microcarcinoma: a systematic review and meta-analysis. World J Surg Oncol 2022; 20: 106
• 36 Yan T, Qiu W, Song J. et al. Bilateral multifocality, a marker for aggressive disease, is not an independent prognostic factor for papillary thyroid microcarcinoma: A propensity score matching analysis. Clin Endocrinol (Oxf) 2021; 95: 209-216
• 37 Castagna MG, Forleo R, Maino F, Fralassi N. et al. Small papillary thyroid carcinoma with minimal extrathyroidal extension should be managed as ATA low-risk tumor. J Endocrinol Invest 2018; 41: 1029-1035
• 38 Silver CE, Owen RP, Rodrigo JP. et al. Aggressive variants of papillary thyroid carcinoma. Head Neck 2011; 33: 1052-1059
• 39 Fahiminiya S, de Kock L, Foulkes WD. Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J Med 2016; 375: 2306-2307
• 40 Pappa T, Ahmadi S, Marqusee E. et al. Oncogenic mutations in PI3K/AKT/mTOR pathway effectors associate with worse prognosis in BRAFV600E-driven papillary thyroid cancer patients. Clin Cancer Res 2021; 27: 4256-4264